Wenjia Zhu1, Yuejuan Cheng2, Xuezhu Wang1, Shaobo Yao3, Chunmei Bai2, Hong Zhao4, Ru Jia5, Jianming Xu5, Li Huo6. 1. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Oncology, Peking Union Medical College Hospital, Beijing, China. 3. Department of PET/CT Diagnostics, General Hospital, Tianjin Medical University Tianjin, China. 4. Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and. 5. Department of Gastrointestinal Oncology, Fifth Medical Center, General Hospital of PLA, Beijing, China. 6. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China huoli@pumch.cn.
Abstract
68Ga-DOTA-JR11 is a somatostatin receptor subtype 2-specific antagonist used for PET/CT imaging. The purpose of this study was to compare 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors. Methods: Patients with histologically proven, metastatic or unresectable, well-differentiated neuroendocrine tumors were prospectively recruited to this study. Each patient received an intravenous injection of 68Ga-DOTATATE (155 ± 52 MBq) on the first day and 68Ga-DOTA-JR11 (148 ± 52 MBq) on the second day. Whole-body PET/CT scans were performed at 40-60 min after injection on the same scanner. Physiologic normal-organ uptake, lesion numbers, and lesion uptake were compared. Results: Thirty-one patients were prospectively enrolled in the study. The SUVmax of the spleen, renal cortex, adrenal glands, pituitary glands, stomach wall, normal liver parenchyma, small intestine, pancreas, and bone marrow was significantly lower on 68Ga-DOTA-JR11 than on 68Ga-DOTATATE PET/CT (P < 0.001). 68Ga-DOTA-JR11 detected significantly more liver lesions (552 vs. 365, P = 0.001) but fewer bone lesions (158 vs. 388, P = 0.016) than 68Ga-DOTATATE. The target-to-background ratio of liver lesions was significantly higher on 68Ga-DOTA-JR11 (7.7 ± 5.4 vs. 3.4 ± 2.0, P < 0.001). 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT showed comparable results for primary tumors and lymph node metastases on both patient-based and lesion-based comparisons. Conclusion: 68Ga-DOTA-JR11 performs better in detecting liver metastases, with a better tumor-to-background ratio, whereas 68Ga-DOTATATE may outperform 68Ga-DOTA-JR11 in the detection of bone metastases. However, the lower somatostatin receptor subtype 2 affinity of 68Ga-DOTA-JR11 than of 177Lu-DOTA-JR11 may limit its role as a diagnostic pair for the theranostic approach with 177Lu-DOTA-JR11.
68Ga-DOTA-JR11 is a somatostatin receptor subtype 2-specific antagonist used for PET/CT imaging. The purpose of this study was to compare 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors. Methods:Patients with histologically proven, metastatic or unresectable, well-differentiated neuroendocrine tumors were prospectively recruited to this study. Each patient received an intravenous injection of 68Ga-DOTATATE (155 ± 52 MBq) on the first day and 68Ga-DOTA-JR11 (148 ± 52 MBq) on the second day. Whole-body PET/CT scans were performed at 40-60 min after injection on the same scanner. Physiologic normal-organ uptake, lesion numbers, and lesion uptake were compared. Results: Thirty-one patients were prospectively enrolled in the study. The SUVmax of the spleen, renal cortex, adrenal glands, pituitary glands, stomach wall, normal liver parenchyma, small intestine, pancreas, and bone marrow was significantly lower on 68Ga-DOTA-JR11 than on 68Ga-DOTATATE PET/CT (P < 0.001). 68Ga-DOTA-JR11 detected significantly more liver lesions (552 vs. 365, P = 0.001) but fewer bone lesions (158 vs. 388, P = 0.016) than 68Ga-DOTATATE. The target-to-background ratio of liver lesions was significantly higher on 68Ga-DOTA-JR11 (7.7 ± 5.4 vs. 3.4 ± 2.0, P < 0.001). 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT showed comparable results for primary tumors and lymph node metastases on both patient-based and lesion-based comparisons. Conclusion:68Ga-DOTA-JR11 performs better in detecting liver metastases, with a better tumor-to-background ratio, whereas 68Ga-DOTATATE may outperform 68Ga-DOTA-JR11 in the detection of bone metastases. However, the lower somatostatin receptor subtype 2 affinity of 68Ga-DOTA-JR11 than of 177Lu-DOTA-JR11 may limit its role as a diagnostic pair for the theranostic approach with 177Lu-DOTA-JR11.
Authors: Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning Journal: N Engl J Med Date: 2017-01-12 Impact factor: 91.245
Authors: Damian Wild; Melpomeni Fani; Martin Behe; Ingo Brink; Jean E F Rivier; Jean Claude Reubi; Helmut R Maecke; Wolfgang A Weber Journal: J Nucl Med Date: 2011-08-18 Impact factor: 10.057
Authors: Maria Werner-Wasik; Arden D Nelson; Walter Choi; Yoshio Arai; Peter F Faulhaber; Patrick Kang; Fabio D Almeida; Ying Xiao; Nitin Ohri; Kristin D Brockway; Jonathan W Piper; Aaron S Nelson Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-29 Impact factor: 7.038
Authors: Guillaume P Nicolas; Rosalba Mansi; Lisa McDougall; Jens Kaufmann; Hakim Bouterfa; Damian Wild; Melpomeni Fani Journal: J Nucl Med Date: 2017-04-27 Impact factor: 10.057
Authors: Damian Wild; Melpomeni Fani; Richard Fischer; Luigi Del Pozzo; Felix Kaul; Simone Krebs; Richard Fischer; Jean E F Rivier; Jean Claude Reubi; Helmut R Maecke; Wolfgang A Weber Journal: J Nucl Med Date: 2014-06-24 Impact factor: 10.057
Authors: Guillaume P Nicolas; Nils Schreiter; Felix Kaul; John Uiters; Hakim Bouterfa; Jens Kaufmann; Tobias E Erlanger; Richard Cathomas; Emanuel Christ; Melpomeni Fani; Damian Wild Journal: J Nucl Med Date: 2017-11-30 Impact factor: 10.057
Authors: Simone Krebs; Neeta Pandit-Taskar; Diane Reidy; Bradley J Beattie; Serge K Lyashchenko; Jason S Lewis; Lisa Bodei; Wolfgang A Weber; Joseph A O'Donoghue Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-29 Impact factor: 9.236
Authors: Guillaume P Nicolas; Seval Beykan; Hakim Bouterfa; Jens Kaufmann; Andreas Bauman; Michael Lassmann; Jean Claude Reubi; Jean E F Rivier; Helmut R Maecke; Melpomeni Fani; Damian Wild Journal: J Nucl Med Date: 2017-10-12 Impact factor: 10.057
Authors: Melpomeni Fani; Friederike Braun; Beatrice Waser; Karin Beetschen; Renzo Cescato; Judit Erchegyi; Jean E Rivier; Wolfgang A Weber; Helmut R Maecke; Jean Claude Reubi Journal: J Nucl Med Date: 2012-07-31 Impact factor: 10.057